retatrutide liver benefits Diagram showing the mechanism of action of Ozempic vs retatrutide: complete comparison

The glucagon receptor adds a second accelerator to intestinal transit on top of the GLP-1 brake-then-release cycle

Current data from clinical trials indicate that retatrutide, administered via subcutaneous injection, demonstrates a predictable and manageable safety profile, consistent with other incretin-based therapeutics

Fasting glucose normalization, improved insulin sensitivity, and better lipid profiles were observed across dose groups, with particular significance at 4mg and above

Our job is to get the right indication and show the safety in a controlled setting. GLP-1 manufacturers may eventually tweak the molecular structure of the drugs to minimize muscle loss

Rapid Dispatch: Lead times of 23 weeks and 24-hour dispatch for stock items are becoming standard competitive differentiators